Biotechnology

Top Employer 2024 certification reflects Boehringer Ingelheim's impactful people development in Asia Pacific

* Boehringer Ingelheim is recognized as one of 17 Top Employers worldwide and for the fifth consecutive year inAsia Pacific * High scores in development and steering (strategy and leadership) practices highlight Boehringer Ingelheim's continued commitment to employee wellbeing and development...

2024-01-18 12:00 2605

Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)

- Data from first tranche of MSS CRC patients treated with ADG126 10 mg/kg every three weeks (Q3W) in dose expansionshowed clinical benefit including confirmed responses at higher, more frequent and repeat doses of the anti-CTLA-4 therapy - - Preliminary survival analysis of ADG126 10 mg/kg do...

2024-01-17 20:00 4300

FIRST PATIENTS ENROLLED IN THE GORE VBX FORWARD CLINICAL STUDY

This study aims to compare the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis primary patency to bare metal stenting to evaluate superiority in treating complex iliac occlusive disease with the goal of informing practice guidelines around which modality is best suited for patients with this...

2024-01-16 21:00 2095

CELLSEARCH® CTC count proves its clinical utility in guiding therapeutic strategy supporting patient care in HR+/HER2- metastatic breast cancer

STIC CTC trial data published this November 2023 in the Journal of Clinical Oncology (JCO)demonstrate that CTC-guided treatment decision confers superior survival benefits in a subgroup of patients with hormone receptor (HR) positive)/human epidermal growth factor receptor (HER) 2 negative metast...

2024-01-16 15:00 2400

SOPHiA GENETICS and Karkinos Healthcare Forge Strategic Partnership to Advance Cancer Research in India

SOPHiA GENETICS technology helps advance cancer research across India SOPHiA GENETICS and Karkinos Healthcare join forces to propel cutting-edge genomic solutions for breakthroughs in personalized cancer care inIndia BOSTON and ROLLE, Switzerland, Jan. 15, 2024 /PRNewswire/ -- SOPHiA GENETICS (N...

2024-01-15 12:00 2616

Subject Enrollment Completed for International Multicenter Comparative Clinical (Phase 3) Study of Boan Biotech's Denosumab

A meeting was also held in Germany to announce the results of the international pharmacokinetic similarity clinical (Phase 1) study BERLIN, Jan. 12, 2024 /PRNewswire/ -- Boan Biotech recently announced that subject enrollment for the international multicenter comparative clinical (Phase 3) study...

2024-01-12 21:15 4162

RemeGen's RC88 Obtained FDA Fast Track Designation, Heralds New Hope for Ovarian Cancer Patients

YANTAI, China, Jan. 12, 2024 /PRNewswire/ -- RemeGen Co. Ltd. ("RemeGen" or "the Company") (9995.HK, 688331.SH), a commercial-stage biotechnology company, announced recently that its independently developed mesothelin (MSLN)-targeting antibody-drug conjugate (ADC), RC88, has been granted Fast Tra...

2024-01-12 18:17 2895

CEO of Kelun-Biotech Dr. Micheal Ge delivered a presentation on The 42nd JPM Annual Healthcare Conference

SAN FRANCISCO, Jan. 11, 2024 /PRNewswire/ -- The 42nd J.P. Morgan Annual Healthcare Conference("JPMHC")2024 is taking place onJanuary 8-11 at San Fracisco,USA, members of Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990.HK, Kelun-Biotech) senior management team participated in the conferen...

2024-01-11 16:32 3179

More accurate tumour treatment thanks to superconductive ASG Superconductors technology

GENOA, Italy and DRESDEN, Germany, Jan. 10, 2024 /PRNewswire/ -- ASG Superconductors' (ASG) MgB2 superconducting technology - already in use for energy and medical applications such as the world's only truly open MROpenEVO magnetic resonance imaging (MRI) system - is at the heart of the worldwide...

2024-01-10 18:49 3677

Novogene Bolsters Global Presence with Expanded PacBio Revio Fleet, Advancing Long-Read Sequencing Applications

SINGAPORE, Jan. 10, 2024 /PRNewswire/ -- Novogene further expands its long-read sequencing capacity with the acquisition of six additional PacBio Revio sequencers, augmenting its fleet of multi-platforms sequencing technology. This strategic investment underline Novogene's commitment to enhancing...

2024-01-10 10:30 3846

GBI Secures Commercial Manufacturing Contract, Solidifying Leadership in Radiopharmaceutical Manufacturing

PLANTATION, Fla., Jan. 9, 2024 /PRNewswire/ -- GBI BioManufacturing, formerly known as Goodwin Biotechnology, proudly announces the signing of its second Master Supply Agreement (MSA) for commercializing a radioimmunoconjugate product. This milestone not only showcases our commitment to advancing...

2024-01-09 22:00 1959

GC Cell's Promising AB-201 Cancer Treatment to Begin Phase 1 Trials Using Lunit AI Platform

South Korea's first CAR-NK cell therapy cleared for human trials in Australia and domestically; Cancer Moonshot participant GC Cell partnering with medical AI leader Lunit to collaborate on AB-201 clinical development YONGIN, South Korea and SYDNEY, Jan. 9, 2024 /PRNewswire/ -- GC Cell

2024-01-09 00:00 2742

Medison Pharma Announces Agreement with Regeneron Pharmaceuticals to Commercialize Libtayo® (cemiplimab) in Multiple Countries

* Libtayo (cemiplimab) is a leading PD-1 inhibitor that has shown efficacy in the treatment of certain patients with cutaneous squamous cell carcinoma, advanced basal cell carcinoma, advanced non-small cell lung cancer and advanced cervical cancer, and is approved by regulatory authorities in m...

2024-01-08 20:30 2159

Guardant Health and Hikma Partner to Offer Cancer Screening and Comprehensive Genomic Profiling Tests in the Middle East and North Africa

PALO ALTO, Calif., Jan. 8, 2024 /PRNewswire/ -- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and Hikma Pharmaceuticals PLC ("Hikma"), a multinational pharmaceutical company, today announced an agreement to promote Guardant Health's portfolio of liquid and tissue biops...

2024-01-08 15:30 2732

2024 Trend Forecast for Cosmetic Surgery & Medical Aesthetics in Singapore

 As the demand for medical aesthetics and cosmetic surgery continues to grow, Dr Ivan Puah, a liposuction and aesthetic doctor from Amaris B. Clinic, identifies a distinct shift in consumer needs inSingapore. SINGAPORE, Jan. 8, 2024 /PRNewswire/ -- Dr Ivan Puah, Medical Director of Amaris B. Cli...

2024-01-08 09:00 612

Juniper Biologics Clinches Prestigious Molecular Science & Technology Acquisition of the Year Award at the Acquisition International M&A Awards 2023

SINGAPORE, Jan. 8, 2024 /PRNewswire/ -- Juniper Biologics ("Juniper"), a global science-led pharmaceutical company headquartered inSingapore, proudly announces its latest achievement, winning the award for Molecular Science & Technology Acquisition of the Year...

2024-01-08 09:00 2757

Kexing Biopharm Introduces Eribulin Mesylate Injection, Expanding Its Overseas Product Portfolio

SHENZHEN, China, Jan. 5, 2024 /PRNewswire/ -- On the morning of January 3, Kexing Biopharm signed an international commercialization cooperation agreement onEribulin Mesylate Injection, securing exclusive commercialization licensing and supply of the product from Xiling Lab Co., Ltd. in 36 countr...

2024-01-05 19:44 4213

Innovations in China's Greater Bay Area: Global Pitch Competition for Startups Announces Winners

SHENZHEN, China, Jan. 5, 2024 /PRNewswire/ -- Thousands of investors, startups, and industry enthusiasts packed the house and tuned in as the 2023 PHBS-CJBS Global Pitch Competition wrapped up. The spectacular grand final event took place in December, revealing the year's winners and other major ...

2024-01-05 18:23 7343

UniFAHS Raises USD 1.4 Million in Seed Funding to Scale Bacteriophage Technology for Sustainable Agriculture

BANGKOK, Jan. 5, 2024 /PRNewswire/ -- UniFAHS , a trailblazing biotechnology company specialising in phage technology for sustainable agriculture and food safety, today announced it has raised overUSD 1.4 million in its seed funding round. This significant step propels the ...

2024-01-05 10:00 3683

Menarini Group and Insilico Medicine Enter Global Exclusive License Agreement for Novel KAT6 Inhibitor for Potential Breast Cancer Treatment and Other Oncology Indications

* KAT6 is an emerging target in hormone sensitive breast tumors and other cancers. Overexpression of KAT6A/B correlates with poor clinical outcomes in patients with ER+/HER2- breast cancer – the most common subtype. * The molecule has demonstrated strong preclinical activity. Insilico present...

2024-01-05 00:19 3848
1 ... 78798081828384 ... 185